Oxaliplatin Eugia (Oxaliplatin)

Oxaliplatin Eug is a platinum‑based agent used in the management of malignancies that are treated with DNA‑cross‑linking chemotherapy.

• Colorectal cancer: enhances tumor response when combined with fluoropyrimidine regimens.
• Gastric cancer: contributes to disease control as part of combination protocols.
• Pancreatic cancer: used in multi‑drug regimens to improve progression‑free survival.

• Oxaliplatin exerts cytotoxic activity by forming covalent adducts with DNA, creating intra‑ and interstrand cross‑links that disrupt DNA replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis, particularly in rapidly dividing tumor cells.

Adverse reactions to Oxaliplatin may vary in frequency and severity.

Common Side Effects

• Peripheral neuropathy: tingling or numbness, often dose‑related.
• Nausea and vomiting: may require anti‑emetic prophylaxis.
• Diarrhoea: can be mild to moderate.
• Fatigue: generalised tiredness during treatment cycles.
• Myelosuppression: reduced blood cell counts.
• Elevated liver enzymes: mild transaminitis.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: including anaphylaxis.
• Acute neurotoxicity: sudden onset of muscle cramps or spasms.
• Persistent peripheral neuropathy: may be long‑lasting after treatment.
• Hemolytic‑uremic syndrome: rare but serious renal complication.
• Cardiac arrhythmias: uncommon electrophysiological disturbances.
• Severe myelosuppression: febrile neutropenia or pancytopenia.

When handling Oxaliplatin Eug, clinicians should observe several safety measures.

• Renal function assessment: evaluate baseline creatinine and eGFR before infusion.
• Hepatic function monitoring: check liver enzymes and bilirubin regularly.
• Neuropathy surveillance: assess sensory changes at each visit.
• Hematologic monitoring: perform complete blood counts prior to each cycle.
• Premedication: consider antihistamines or steroids to reduce infusion reactions.
• Store at below 25°C: keep in the original container, protect from light and moisture.

Oxaliplatin may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Nephrotoxic agents: concurrent use can worsen renal impairment.
• High‑dose vitamin C: may reduce platinum‑drug activity.
• Live vaccines: immunosuppression increases infection risk.

Moderate Interactions (Monitor Closely)

• Anticoagulants: heightened bleeding risk during thrombocytopenia.
• Other neurotoxic chemotherapy: additive peripheral neuropathy.
• CYP‑modulating drugs: may affect supportive‑care medication metabolism.